Pharma
Stay updated with the latest happenings in the pharmaceutical industry. Get insights into drug development, innovations, regulatory updates, and emerging trends. Discover the advancements shaping the future of healthcare. Explore the world of pharma with our comprehensive coverage at Pharmtales.com.
Contamination Worries Prompt Scynexis to Recall Brexafemme, Putting Trials on Hold Following GSKās Manufacturing Review
In a surprising development, Scynexis is taking a precautionary step to withdraw its antifungal medication, ibrexafungerp, marketed as Brexafemme, from ...
Morphicās Shares Tumble as Updated Phase 2 Data Casts Shadows on Takedaās Entyvio Rival
Morphic Therapeutic has encountered a setback, as more comprehensive data from its much-anticipated EMERALD-1 trial unveiled uncertainties, causing its stock ...
AbbVie Withdraws from CD47 Arena, Ending Partnership with I-Mab
AbbVie has officially distanced itself from I-Mab, withdrawing from a once-promising collaboration focused on the anti-CD47 antibody lemzoparlimab, leaving I-Mab ...
Revivicor Breaks Ground in Xenotransplantation, Achieving Two Months of Stable Function in a Genetically Engineered Kidney
Revivicor, a division of United Therapeutics, has unveiled a groundbreaking advancement in organ manufacturing technology, using genetically engineered tissues from ...
VistaPharm Initiates Recall of Ulcer Medication Over Bacterial Contamination Concerns
The pharmaceutical landscape has witnessed several recalls initiated by the FDA due to drugs being contaminated with a spectrum of ...
Bayer and Hologic partner to promote contrast-enhanced mammography for breast cancer diagnosis
Bayer and Hologic have joined forces with the aim of providing enhanced breast cancer scans by combining Bayer’s imaging contrast ...
ImmunityBio cuts 50 jobs in California and Florida after FDA snubs its bladder cancer drug
Following an FDA rejection earlier this year, ImmunityBio has initiated its second round of layoffs in less than a year, ...
Antios shuts down after FDA halts its hepatitis B drug ATI-2173
Antios Therapeutics, a biotech company focused on viral diseases, ceased its operations earlier this year following an FDA-imposed hold on ...
Glenmark sells API business to Nirma for $681M, wipes out debt
Glenmark Pharmaceuticals has successfully resolved its long-standing debt issue by divesting 75% of its active pharmaceutical ingredient (API) business. The ...
Opdivo plus chemo reduces recurrence risk in early-stage lung cancer surgery
In the arena of perioperative treatment for early-stage non-small cell lung cancer (NSCLC) involving PD-1/L1 inhibitors, the competition among key ...
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Keytruda-Lenvima combo fails to improve survival in two lung cancer trials
Merck and Eisai’s collaborative effort with Keytruda and Lenvima faces yet another setback in their quest to combat cancer. Despite ...
Jardiance gets FDA green light for chronic kidney disease, challenging AstraZenecaās rival drug
Shortly after securing European approval for the treatment of chronic kidney disease (CKD), Eli Lilly and Boehringer Ingelheim have achieved ...
Virtual Incision secures $30M funding to expand its mini-robot for laparoscopic surgery
A diminutive robot is making a significant financial stride. Virtual Incision, a pioneer in assisted surgery technology, has secured a ...
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
Abpro to go public via SPAC merger with Atlantic Coastal, raising funds for its HER2xCD3 bispecific and COVID-19 program
Abpro is making a return to the public market after a five-year hiatus, this time teaming up with Atlantic Coastal ...
Filspari fails to confirm kidney benefit in IgAN, but Travere hopes to keep FDA approval
Half a year after securing accelerated approval for the treatment of a rare kidney ailment, Travere Therapeuticsā groundbreaking drug, Filspari, ...
NICE approves Lillyās Omvoh for ulcerative colitis after FDA rejection, citing cost-effectiveness and clinical benefits
“In a significant turn of events, Eli Lilly, despite initial setbacks in the US market with its ulcerative colitis drug ...
Aurinia appoints founder and former CEO Robert Foster to board as part of cooperation agreement with MKT Capital
Aurinia Pharmaceuticals, known for its focus on autoimmune diseases, has taken steps to address investor concerns by appointing its founder ...
Takeda reaches settlement with drug wholesalers over alleged pay-for-delay scheme for Colcrys
Takeda, the Japanese pharmaceutical giant, has reached a settlement in an antitrust case that has been looming over the company. ...
Roche wins patent appeal over Hemlibra, its hemophilia A drug, against Takedaās Baxalta
In a patent dispute revolving around two competing hemophilia medications, Roche’s Genentech unit has achieved its second consecutive victory. Following ...
Eric Stonestreet, ‘Modern Family’ Actor, Joins Forces with Astellas’ Iveric Bio to Launch Vision Health Awareness Initiative
Iveric Bio, an Astellas-acquired biotech company, has initiated a compelling awareness campaign for a disease it recently gained FDA approval ...
Novo Nordisk Foundation Cellerator to boost cell therapy development and production in Denmark
The Novo Nordisk Foundation is embarking on a mission to establish a pivotal “hub” within the cell therapy ecosystem by ...
Gallup poll shows pharma industryās reputation plunges to record low amid COVID-19 vaccine criticism
The pharmaceutical industry’s reputation in the United States has reached its lowest point in the 21st century, with a significant ...
Relmada reports positive results from open-label trial of REL-1017 for major depressive disorder
Relmada Therapeutics, a central-nervous-system-focused biotech company, has finally glimpsed a ray of optimism after facing setbacks in two phase 3 ...
Mesoblast hopes to win FDA approval for remestemcel-L after meeting with regulators
Mesoblast, a biotech company based in Melbourne, Australia, is making determined strides toward securing FDA approval for its off-the-shelf therapy, ...
Inventiva and Kezar partner with Asian biotechs to advance NASH and lupus drugs
In a strategic move, Inventiva and Kezar Life Sciences have successfully secured buyers for the Asian rights to their lead ...
Roche fined for serious breach of marketing code by failing to disclose safety data
Roche, a prominent pharmaceutical company, is under scrutiny for omitting vital safety details from a webpage dedicated to dosing information ...
UCB’s psoriasis drug application overcomes manufacturing hurdle but hits another FDA delay
After facing delays related to manufacturing issues, UCB’s psoriasis medication, bimekizumab, is awaiting the next steps in its FDA review ...
Rising Pharmaceuticals opens former Akorn plant to produce sterile injectables and ophthalmics
Rising Pharmaceuticals, a prominent generic drug manufacturer, has inaugurated a manufacturing facility with a specific focus on injectable and ophthalmic ...
